You just read:

Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias

News provided by

Syndax Pharmaceuticals, Inc.

Jul 10, 2019, 07:00 ET